Cwh43 Antibody

What is CWH43 and what are its primary functions in mammalian cells?

CWH43 (Cell Wall Biogenesis 43 C-Terminal Homolog) is a protein that plays a crucial role in modifying the lipid anchor of glycosylphosphatidylinositol (GPI)-anchored proteins. Research has demonstrated that CWH43 regulates the membrane localization of GPI-anchored proteins in mammalian cells . The protein functions by affecting how GPI-anchored proteins associate with lipid microdomains, which are critical for proper cellular signaling and membrane organization.

Methodologically, this has been established through cell fractionation experiments using Triton X-114 to separate aqueous and lipid compartments, followed by Western blot analysis to detect the distribution of GPI-anchored proteins like CD59. In cells with wild-type CWH43, GPI-anchored proteins predominantly localize to lipid microdomains, whereas mutations in CWH43 disrupt this localization pattern .

Where is CWH43 primarily expressed in the brain and other tissues?

In mouse models, CWH43 shows distinctive expression patterns in the brain. In situ hybridization studies reveal increased CWH43 mRNA expression in the choroid plexus, layers CA1-CA3 of the hippocampus, several thalamic nuclei, and layer V of the cerebral cortex . Immunohistochemical analysis of mouse brain sections shows that CWH43 protein is particularly concentrated in the ventricular ependymal layer and choroid plexus . In cultured ependymal cells, CWH43 immunoreactivity is observed in both the cell soma and in motile cilia .

For researchers investigating CWH43 expression, it's advisable to employ multiple complementary techniques including in situ hybridization, immunohistochemistry, and Western blotting to comprehensively map its distribution across tissues and subcellular compartments.

How are mutations in CWH43 linked to idiopathic normal pressure hydrocephalus (iNPH)?

Research using whole exome sequencing of 53 unrelated iNPH patients identified two recurrent heterozygous loss-of-function deletions in CWH43 that were significantly enriched (6.6-fold and 2.7-fold, respectively) compared to the general population . These genetic findings establish a causal relationship between CWH43 mutations and iNPH.

The mechanistic link has been elucidated in mouse models heterozygous for CWH43 deletion, which displayed hydrocephalus, gait and balance abnormalities, decreased numbers of ependymal cilia, and reduced localization of GPI-anchored proteins to the apical surfaces of choroid plexus and ependymal cells . These findings suggest that proper functioning of CWH43 is essential for cerebrospinal fluid dynamics and ependymal cell function, disruption of which leads to hydrocephalus.

For researchers studying this relationship, a multidisciplinary approach combining genetic analysis, animal models, and cellular studies would be most informative.

What evidence supports CWH43's role as a tumor suppressor gene in colorectal cancer (CRC)?

Multiple lines of evidence support CWH43's tumor suppressor function in CRC:

Researchers investigating CWH43 in cancer should consider both expression analysis in patient samples and functional characterization in cell and animal models to fully elucidate its role.

What are the optimal conditions for using CWH43 antibodies in immunohistochemistry (IHC) applications?

Based on available information for commercial CWH43 antibodies, the following methodological recommendations can be made:

For paraffin-embedded tissue sections:

• Optimal dilution range: 1:50-1:200 for Prestige Antibodies and 1:500-1:1000 for Novus Biologicals polyclonal antibody

• Antigen retrieval: Heat-induced epitope retrieval is typically required (specific buffer composition should be optimized)

• Detection system: Use of high-sensitivity polymer-based detection systems is recommended

• Counterstaining: Hematoxylin for nuclear visualization

It's advisable to include positive and negative controls:

• Positive controls: Tissues known to express CWH43 (choroid plexus, ependymal cells)

• Negative controls: Primary antibody omission and tissues known to lack CWH43 expression

Researchers should perform antibody validation using tissues from CWH43 knockout models or siRNA-treated cells to confirm specificity.

How can researchers validate the specificity of CWH43 antibodies for their experiments?

Rigorous validation of CWH43 antibodies should involve multiple approaches:

• Western blot analysis:

  • Compare protein detection in cell lines with normal, overexpressed, and knocked-down CWH43 levels

  • Verify that the detected band is at the expected molecular weight

  • Check for absence of non-specific bands

• Immunocytochemistry/Immunohistochemistry controls:

  • Use CRISPR/Cas9-edited cells lacking CWH43 as negative controls

  • Compare staining patterns with known expression data from mRNA studies

  • Perform peptide competition assays using the immunizing peptide

• Cross-validation with different antibodies:

  • Compare results from different CWH43 antibodies targeting distinct epitopes

  • Correlate with data from mRNA expression (RT-PCR or in situ hybridization)

• Protein array screening:

  • Commercial antibodies like the Prestige Antibodies are tested against protein arrays containing 364 human recombinant protein fragments to ensure low cross-reactivity

  • Researchers can perform similar validation if working with novel antibodies

A comprehensive validation approach increases confidence in antibody specificity and experimental results.

How can CWH43 antibodies be used to investigate GPI-anchored protein trafficking in live cells?

For investigating dynamic trafficking of GPI-anchored proteins in relation to CWH43 function, researchers can employ the following methodological approach:

• Create fluorescently tagged CWH43 constructs:

  • GFP-CWH43 fusion proteins have been successfully used in previous studies

  • Both wild-type and mutant (Leu533Ter or Lys696AsnfsTer23) variants should be included

• Combine with fluorescently tagged GPI-anchored proteins:

  • RFP-CD59 or RFP-Folate receptor alpha constructs can be co-expressed with CWH43 variants

  • This allows for dual-color live imaging of both proteins

• Implementation of live-cell imaging techniques:

  • High-resolution confocal microscopy with temperature and CO₂ control

  • Total internal reflection fluorescence (TIRF) microscopy for membrane-specific imaging

  • Fluorescence recovery after photobleaching (FRAP) to measure mobility of GPI-anchored proteins

• Organelle labeling:

  • Use of RFP-calreticulin-KDEL to visualize the endoplasmic reticulum

  • Anti-golgin-97 antibody staining to visualize the Golgi apparatus

This multimodal approach would provide insights into how CWH43 influences the intracellular trafficking, membrane distribution, and dynamics of GPI-anchored proteins.

What methodological approaches can address contradictions in CWH43 knockout phenotypes between different cell types?

When confronting contradictory phenotypes in CWH43 knockout studies across different cell types, researchers should consider a systematic approach:

• Comprehensive characterization of CWH43 expression levels across cell types:

  • Quantitative RT-PCR and Western blotting to establish baseline expression

  • Analysis of potential splice variants that might be differentially expressed

• Generation of consistent knockout models:

  • Use identical CRISPR/Cas9 targeting strategies across cell lines

  • Verify knockout efficiency through genomic sequencing, mRNA analysis, and protein detection

• Controlled rescue experiments:

  • Re-expression of wild-type CWH43 in knockout cells

  • Expression of mutant variants to identify domain-specific functions

• Comparative functional assays:

  • Analysis of GPI-anchored protein distribution using Triton X-114 extractions and Western blotting

  • Flow cytometry to quantify surface expression of GPI-anchored proteins

  • Subcellular fractionation to detect changes in protein localization

• Exploration of cell-type-specific factors:

  • Analysis of interacting partners unique to specific cell types

  • Investigation of compensatory mechanisms that might be active in certain cellular contexts

This comprehensive approach helps resolve contradictions by identifying cell-type-specific factors that modify CWH43 function.

How might CWH43 function be explored as a therapeutic target for cancer treatment?

Given CWH43's role as a tumor suppressor in colorectal cancer , several methodological approaches could explore its therapeutic potential:

• Development of CWH43 expression restoration strategies:

  • Design of epigenetic modulators to reverse potential CWH43 promoter methylation

  • Development of CRISPR activation (CRISPRa) systems targeting the CWH43 locus

  • Viral vector-mediated CWH43 expression for cancer cells

• Identification of downstream effectors:

  • Proteomics and transcriptomics analysis of CWH43-overexpressing versus control cells

  • Pathway analysis focusing on epithelial-mesenchymal transition and cell cycle regulation

  • Validation of key nodes using pharmacological inhibitors

• High-throughput screening for CWH43 function modulators:

  • Development of reporter systems reflecting CWH43 activity

  • Small molecule screening to identify compounds that enhance CWH43 expression or function

  • Testing of hit compounds in cell-based and animal models

• Synthetic lethality approaches:

  • Identification of genes whose inhibition is selectively lethal in CWH43-deficient cells

  • Validation in patient-derived xenograft models with varying CWH43 expression levels

These approaches provide a framework for exploring CWH43 as a potential therapeutic target or biomarker in cancer management.

What techniques can be employed to study the interaction between CWH43 and other proteins involved in GPI-anchor remodeling?

To investigate protein interactions with CWH43, researchers should consider these methodological approaches:

• Proximity-based interaction mapping:

  • BioID or TurboID fusion proteins to identify proximal interacting partners

  • APEX2-based proximity labeling coupled with mass spectrometry

  • FRET/BRET approaches for specific candidate interactions

• Co-immunoprecipitation strategies:

  • Endogenous co-IP using validated CWH43 antibodies

  • GFP-trap pulldown of GFP-CWH43 fusion proteins

  • Reciprocal co-IP with antibodies against putative interacting partners

• Membrane protein interaction analysis:

  • Crosslinking mass spectrometry (XL-MS) optimized for membrane proteins

  • Membrane yeast two-hybrid systems

  • Native PAGE analysis followed by Western blotting

• Subcellular co-localization studies:

  • High-resolution confocal imaging with antibodies against CWH43 and potential partners

  • Super-resolution microscopy (STORM/PALM) for nanoscale localization

  • Live-cell imaging with dual-labeled proteins

• Functional interaction validation:

  • Mutational analysis of interaction domains

  • Competitive peptide inhibition studies

  • Reconstitution of GPI-anchor remodeling activity in cell-free systems

These approaches would help construct a comprehensive protein interaction network centered on CWH43 and illuminate its functional role in GPI-anchor remodeling.

What are the key considerations when designing experiments to compare wild-type and mutant CWH43 functions?

When comparing wild-type and mutant CWH43 functions, researchers should address these methodological considerations:

• Model selection and generation:

  • Cell lines with endogenous CWH43 expression vs. knockout background for reintroduction

  • Generation of isogenic cell lines using CRISPR/Cas9 to introduce specific mutations

  • Primary cells vs. established cell lines for physiological relevance

• Expression control:

  • Use of inducible expression systems to control expression timing and levels

  • Normalization of protein expression levels between wild-type and mutant constructs

  • Single-cell analysis to account for heterogeneous expression

• Mutant selection:

  • Include the disease-associated mutations (Leu533Ter and Lys696AsnfsTer23)

  • Generate domain-specific mutations to map functional regions

  • Consider evolutionary conservation when selecting residues for mutagenesis

• Functional readouts:

  • GPI-anchored protein localization using subcellular fractionation

  • Membrane microdomain association using Triton X-114 extraction

  • Cell biological phenotypes relevant to disease (proliferation, migration for cancer studies)

• Controls and validation:

  • Rescue experiments to confirm specificity of observed phenotypes

  • Use of multiple independent clones to account for clonal variation

  • Parallel analysis in multiple cell types to assess context-dependence

This systematic approach ensures robust and reproducible comparison of wild-type and mutant CWH43 functions.

How should researchers interpret conflicting data regarding CWH43 expression in different tissue types or disease states?

When confronted with conflicting data on CWH43 expression, researchers should implement this analytical framework:

• Technical validation:

  • Cross-comparison of antibody specificity using multiple validated antibodies

  • Correlation of protein detection with mRNA expression data

  • Assessment of sample preparation methods that might affect detection

• Contextual analysis:

  • Evaluation of tissue heterogeneity and cell-type specific expression

  • Consideration of developmental stage and disease progression effects

  • Analysis of potential splice variants or post-translational modifications

• Quantitative assessment:

  • Use of absolute quantification methods like digital PCR for mRNA

  • Targeted proteomics approaches with internal standards for protein quantification

  • Single-cell analysis to resolve population heterogeneity

• Metadata integration:

  • Systematic review of experimental conditions across studies

  • Integration of data from multiple independent datasets

  • Application of meta-analysis approaches to identify consistent patterns

• Orthogonal validation:

  • Functional studies to correlate expression with biological effects

  • In vivo validation of findings from cell culture models

  • Multi-omics integration (transcriptomics, proteomics, metabolomics)

This approach allows researchers to resolve apparent contradictions and develop a more nuanced understanding of context-dependent CWH43 expression patterns.